Develops lipid nanoparticle drug delivery systems using proprietary Artificial Membrane-Binding Protein (AMBP) technology to improve the efficiency and targeting of therapeutic agents. This approach addresses challenges in drug stability, bioavailability, and cellular uptake, enabling more effective treatments for a range of diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many therapeutic agents face challenges related to drug stability, bioavailability, and effective cellular uptake, hindering their efficacy in treating various diseases. Traditional drug delivery systems often lack the precision to target specific cells or tissues, leading to off-target effects and reduced therapeutic outcomes.
Solution
Hone Bio is developing lipid nanoparticle (LNP) drug delivery systems leveraging proprietary Artificial Membrane-Binding Protein (AMBP) technology to enhance the efficiency and targeting of therapeutic agents. The AMBP technology aims to improve drug stability within the LNP, increase bioavailability by facilitating cellular uptake, and enable precise targeting of specific cells or tissues. This targeted approach seeks to minimize off-target effects, maximize therapeutic impact, and ultimately enable more effective treatments for a range of diseases.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions developing novel therapeutic agents that require improved delivery systems for enhanced efficacy and reduced toxicity.
Features
- Proprietary Artificial Membrane-Binding Protein (AMBP) technology for enhanced LNP targeting.
- Improved drug stability within the lipid nanoparticle.
- Increased bioavailability through enhanced cellular uptake mechanisms.
- Potential for reduced off-target effects due to precise targeting.